Showing results (91-100 of 180) with videos related to
Sort By:
Pageof 18
Haematologica|December 11, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcomeStephen P Robinson, Anna Sureda, Carmen Canals, et al.British Journal of Haematology|January 22, 2022
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.Haematologica|August 4, 2009
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionBella Patel, Keiren E Kirkland, Richard Szydlo, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) TrialChristopher Parrish, Curly T C M Morris, Cathy D Williams, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.The Lancet. Oncology|June 21, 2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trialGordon Cook, Cathy Williams, Julia M Brown, et al.Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.British Journal of Haematology|December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trialMatthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.Pageof 18